Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProCP-1
- Development stage
- Discontinued
- Lead developer
- Pro-CP
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ProCP-1 is a recombinant human procarboxypeptidase B (specifically the pancreatic isoform, CPB1) developed for the treatment of acute pancreatitis. It acts as a pro-enzyme that, when activated to carboxypeptidase B, specifically cleaves the C-terminal arginine residues from the anaphylatoxins C3a and C5a, thereby inactivating them. By neutralizing these potent inflammatory mediators, ProCP-1 aims to reduce the systemic inflammatory response syndrome (SIRS) and multi-organ failure associated with severe acute pancreatitis. The drug was developed by the Dutch biotechnology company Pro-CP B.V. and reached Phase 1/2 clinical testing.
- Other names
- recombinant human procarboxypeptidase BrhProCPBCPB1CPB-1CPB 1
02
Targets
Complement component C5aC3AR1 (Complement C3a receptor)
Beyond the preview
Go deeper on ProCP-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProCP-1.